Phase 1 Recurrent Clinical Trials
295 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 295 trials
Recruiting
Phase 1
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8Recurrent Breast CarcinomaInvasive Breast Carcinoma+2 more
Mayo Clinic54 enrolled1 locationNCT04521764
Recruiting
Phase 1Phase 2
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Phase 1
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
High Grade GliomaLow-grade GliomaRecurrent World Health Organization (WHO) Grade II Glioma
University of California, San Francisco50 enrolled17 locationsNCT04485559
Recruiting
Phase 1
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic Therapy
National Cancer Institute (NCI)47 enrolled6 locationsNCT07012044
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924
Recruiting
Phase 1
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC)Carcinoma, AdrenocorticalCarcinoma, Adrenal Cortical+2 more
National Cancer Institute (NCI)32 enrolled1 locationNCT06487481
Recruiting
Phase 1Phase 2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center30 enrolled1 locationNCT05263284
Recruiting
Phase 1
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
GlioblastomaGliomaRecurrent Glioblastoma+2 more
Kailin Yang, MD, PhD45 enrolled1 locationNCT07541781
Recruiting
Phase 1
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center12 enrolled1 locationNCT07025564
Recruiting
Phase 1
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Ovarian CancerOvarian CarcinomaPlatinum Resistant Ovarian Cancer+4 more
Dana-Farber Cancer Institute18 enrolled2 locationsNCT06321484
Recruiting
Phase 1
Chronic CED of TPT for Recurrent Malignant Glioma
Brain Tumor, RecurrentMalignant Glioma (WHO Grade III or IV)IDH1/IDH2 Mutation
Jeffrey N. Bruce6 enrolled1 locationNCT06666712
Recruiting
Phase 1Phase 2
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Phase 1
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
Resectable Brain NeoplasmRecurrent Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Malignant Brain Neoplasm
University of Michigan Rogel Cancer Center11 enrolled1 locationNCT06914479
Recruiting
Phase 1Phase 2
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
Glioblastoma (GBM)Recurrent GlioblastomaNewly Diagnosed Glioblastoma+1 more
Trogenix ltd68 enrolled2 locationsNCT07346144
Recruiting
Phase 1
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Recurrent Endometrial CarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)65 enrolled14 locationsNCT05950464
Recruiting
Phase 1Phase 2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Ovarian Cancer Recurrent
Merck Sharp & Dohme LLC460 enrolled23 locationsNCT06843447
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Unresectable Head and Neck Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8+27 more
National Cancer Institute (NCI)39 enrolled1 locationNCT07156227
Recruiting
Phase 1
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Follicular Lymphoma ( FL)Diffuse Large B Cell Lymphoma RefractoryPrimary Mediastinal Large B-Cell Lymphoma Refractory+3 more
GenomeFrontier Therapeutics TW Co., Ltd.18 enrolled1 locationNCT06703892
Recruiting
Phase 1
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+6 more
National Cancer Institute (NCI)54 enrolled22 locationsNCT06484062